ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI's stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $5.78 and traded as high as $6.24. ESSA Pharma shares last traded at $5.95, with a volume of 19,742 shares trading hands.
ESSA Pharma Stock Up 2.9 %
The firm has a market capitalization of $271.50 million, a P/E ratio of -9.71 and a beta of 1.83. The company has a fifty day simple moving average of $5.81 and a 200 day simple moving average of $5.91.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. As a group, equities analysts expect that ESSA Pharma Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ESSA Pharma
An institutional investor recently raised its position in ESSA Pharma stock. Janus Henderson Group PLC boosted its holdings in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 7.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,175,242 shares of the company's stock after acquiring an additional 85,760 shares during the quarter. Janus Henderson Group PLC owned 2.66% of ESSA Pharma worth $9,978,000 at the end of the most recent quarter. 75.12% of the stock is currently owned by institutional investors and hedge funds.
About ESSA Pharma
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
